Investment
Features
FeesSafety
Academy
More
Pluang+

Himax's ultralow power AI powers Alibaba's new Qwen Glasses for extended battery life.

Market News
14 Oct 2026
GlobeNewsWire
View Source
Bullish
Himax's ultralow power AI powers Alibaba's new Qwen Glasses for extended battery life.

Himax Technologies announced its WiseEye ultralow power AI processor is integrated into Alibaba's Qwen Glasses N1 series, enabling an always-on visual sensing system that significantly extends battery life. The AI processor uses advanced low-power architecture to continuously sense the environment and selectively wake the host system only when needed, reducing power consumption. This technology supports the evolution of smart glasses into proactive AI assistants that understand user context and provide real-time support, marking a key step in wearable AI development.

Himax Technologies' WiseEye ultralow power AI processor integration in Alibaba's Qwen Glasses offers context for technology enthusiasts. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 14, 2026 17:11 WIB: Of 150 priced Technology-sector US stocks, 65 rose and 75 fell today. Notable movers include ATOM at USD 3.87 with a 1-day change of +1.84% and 100% buy order activity, INFY at USD 11.60 with a 1-day change of +1.75% and 74% sell order activity, and WDC at USD 374.13 with a 1-day change of -1.73% and 65% sell order activity.

More News

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, contin...

Others
Bullish
1 hour ago
Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...

Market News
Bullish
2 hours ago
FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...

Market News
Bullish
2 hours ago
DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...

Company Fundamentals
Neutral
2 hours ago
Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App